Shall We Dance: Evolving Partnerships of Targeted Therapies for AML
- PMID: 35452083
- DOI: 10.1158/1078-0432.CCR-22-0279
Shall We Dance: Evolving Partnerships of Targeted Therapies for AML
Abstract
Two publications detailing the clinical outcomes of patients with acute myeloid leukemia and mutations in IDH1, IDH2, or FLT3 who received initial therapy with venetoclax and azacitidine provide new insights into risk stratification and set the stage for future trials integrating molecularly targeted therapy with this new standard regimen. See related articles by Konopleva et al., p. 2744 and Pollyea et al., p. 2753.
©2022 American Association for Cancer Research.
Comment on
-
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.Clin Cancer Res. 2022 Jul 1;28(13):2753-2761. doi: 10.1158/1078-0432.CCR-21-3467. Clin Cancer Res. 2022. PMID: 35046058 Free PMC article.
-
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.Clin Cancer Res. 2022 Jul 1;28(13):2744-2752. doi: 10.1158/1078-0432.CCR-21-3405. Clin Cancer Res. 2022. PMID: 35063965 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous